Transgene to present new positive preliminary Phase I data on TG4050
Category: Myvac
First Head & Neck Cancer Patient Enrolled in the UK in a Phase I Trial with TG4050 (myvac® Platform), Transgene’s Innovative Individualized Immunotherapy
First Head & Neck Cancer Patient Enrolled in the UK in a Phase I Trial with TG4050 (myvac® Platform), Transgene’s Innovative Individualized Immunotherapy
Transgene to Present its Immuno-Oncology Expertise at Upcoming Scientific Conferences
20210302 – Transgene Scientific Conferences
First Head & Neck Cancer Patient Treated in France in a Phase I trial with TG4050 (myvac® Platform), Transgene’s Innovative Individualized Immunotherapy
20210121 TG4050 1st patient HNSCC EN
Transgene, NEC and BostonGene Announce Strategic Collaboration for Two Ongoing Clinical Trials for Patients with Ovarian and Head & Neck Cancers
20201006 Transgene_NEC_BostonGene_Press_Release_final
Transgene and Hypertrust Patient Data Care announce successful go-live of the world’s first blockchain solution for clinical trials of personalized healthcare
20200709 PR Hypertrust Transgene EN
Performance of neoantigen prediction for the design of TG4050, a patient specific neoantigen cancer vaccine
AACR2020 myvac B. Mallone et al. AACR 2020 Download the poster here Poster Presentation
Transgene presents promising new data from its next-generation immunotherapy platforms at AACR 2020
20200622a – Transgene PR AACR 3 posters
Transgene and NEC demonstrate high accuracy of AI-based neoantigen prediction for the design of individualized cancer vaccine TG4050
20200515_AACR myvac curtain raiser EN
Transgene Receives Approval from the French Health Authority (ANSM) to Initiate Two Clinical Trials of its Lead myvac® Individualized Immunotherapy TG4050
20190916 PR ANSM TG4050 EN